Stay updated with breaking news from Scottl Friedman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SAN MATEO, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional
A large Swedish cohort study finds a significant protective association between statin use and liver disease progression in adults with non-cirrhotic chronic liver disease.
Researchers have uncovered a network of cell-to-cell communication driving scarring as liver disease advances, which could lead to novel drug targets for non-alcoholic fatty liver disease.
Using the latest technologies-;including both single-nuclear sequencing of mice and human liver tissue and advanced 3D glass imaging of mice to characterize key scar-producing liver cells-;researchers have uncovered novel candidate drug targets for non-alcoholic fatty liver disease (NAFLD).
Using innovative methods, the investigators discovered a network of cell-to-cell communication driving scarring as the liver disease advances. The findings, published in Science Translational Medicine, could lead to new treatments for non-alcoholic fatty liver disease (NAFLD).